

	Metformin (n=238)*	Placebo (n=240)*	Odds ratio (95% CI) or mean difference (95% CI)†	p value
Primary outcomes				
Late miscarriage and preterm delivery	12 (5%)	23 (10%)	0.50 (0.22 to 1.08)	0.08
Late miscarriage	3 (1%)	5 (2%)	0.60 (0.09 to 3.13)	0.72
Preterm delivery	9 (4%)	18 (8%)	0.48 (0.19 to 1.16)	0.11
Gestational length at delivery (days)	280 (268–292)	282 (267–297)	..	0.36
Secondary outcomes				
Gestational diabetes	60 (25%)	57 (24%)	1.09 (0.69 to 1.66)	0.75
At inclusion‡	21 (9%)	22 (9%)	0.96 (0.49 to 1.89)	1.00
After inclusion§	39 (16%)	35 (15%)	1.15 (0.68 to 1.95)	0.61
Hypertension in pregnancy	16 (7%)	13 (5%)	1.25 (0.55 to 2.94)	0.57
Pre-existing hypertension	6 (3%)	3 (1%)
Pre-eclampsia	8 (3%)	17 (7%)	0.46 (0.17 to 1.15)	0.10
Vaginal progesterone treatment because of imminent labour	3 (1%)	3 (1%)
Admission to hospital during pregnancy	49 (21%)	55 (23%)	0.88 (0.55 to 1.37)	0.58
Transfer to neonatal intensive care unit	26 (11%)	24 (10%)	1.10 (0.59 to 2.08)	0.77
Neonate readmitted to hospital¶	14 (6%)	14 (6%)	1.05 (0.64 to 1.41)	0.85
Tertiary and post-hoc outcomes				
Weight gain until week 36 (kg)	9.1 (5.1)**	11.5 (4.9)††	−2.4 (−3.4 to −1.4)	<0.0001
Method of delivery‡‡				
Spontaneous vaginal§§	167 (70%)	169 (70%)	1.01 (0.67 to 1.51)	1.00
Instrumental vaginal	26 (11%)	26 (11%)	1.01 (0.54 to 1.88)	1.00
Caesarean section	45 (19%)	45 (19%)	0.98 (0.60 to 1.61)	1.00
Elective	15 (33%)	10 (22%)	1.42 (0.58 to 3.70)	0.41
Emergency¶¶	30 (67%)	35 (78%)	0.81 (0.46 to 1.43)	0.50
Estimated bleeding (mL)‡‡	300 (49–551)	350 (150–550)***	..	0.16
Post-partum haemorrhage (≥1000 mL)‡‡	10/233 (4%)	11/234 (5%)	0.91 (0.38 to 2.00)	0.83
Placental weight (g)‡‡	680 (241)†††	658 (143)‡‡‡	21.2 (−16.9 to 59.4)	0.28
Perinatal neonate death§§§	1/238 (<1%)	0
Intrauterine fetal death	0	1/240 (<1%)
Birthweight (g)	3488 (560)¶¶¶¶	3453 (633)¶¶¶¶	−35 (−108 to 38)	0.35
Birth length (cm)	50.1 (3.0)	49.8 (3.0)	−0.3 (−0.6 to 0.4)	0.09
Mean head circumference (cm)	35.2 (2.0)***	34.8 (2.0)****	−0.4 (−0.6 to −0.1)	0.006
5 min Apgar score <7	8/233 (3%)	7/232 (3%)	1.16 (0.41 to 3.23)	1.00
Umbilical cord pH	7.26 (0.10)††††	7.26 (0.10)‡‡‡‡	<0.00 (−0.02 to 0.02)**	0.95
Offspring sex‡‡				
Female	114/236 (48%)	112/237 (47%)
Male	122/236 (52%)	125/237 (53%)

Data are n (%), median (IQR), mean (SD), or n/N (%), unless otherwise specified. *Nine patients were excluded from the analysis. †Data are odds ratio (95% CI) for dichotomous variables or mean difference (95% CI) for continuous variables. ‡Five participants in the metformin group and one in the control group had missing data (included in the denominator for percentage calculation). §One participant in the placebo group had missing data (included in the denominator for percentage calculation). ¶Within 8 weeks after discharge from the delivery department. ||85 women were missing data on weight gain: 31 delivered before week 36, 46 withdrew, and three had weight gain information missing on their case report form. **n=198. ††n=200. ‡‡Not predefined endpoints of the study. §§We included late miscarriages in vaginal deliveries (three patients in the metformin group and five in the placebo group). ¶¶Emergency included all non-planned caesareans. ||||n=233. ***n=234. †††n=213. ‡‡‡n=218. §§§Classified as death of the fetus or neonate at 22 + 6 weeks or later (or weight 500 g or greater) until 4 weeks after delivery. ¶¶¶¶n=235. |||||n=230. ****n=232. ††††n=151. ‡‡‡‡n=158.

Table 2: Pregnancy outcomes in the intention-to-treat population